[
  {
    "objectID": "posts.html",
    "href": "posts.html",
    "title": "Frequently asked questions for speakers, session chairs, and panelists",
    "section": "",
    "text": "Scope and contact\nThis document provides necessary information for contributors to the workshop. For any further questions please do not hesitate to reach out to one of the local organizing committee members."
  },
  {
    "objectID": "teaching.html",
    "href": "teaching.html",
    "title": "Frequently asked questions for speakers, session chairs, and panelists",
    "section": "",
    "text": "Scope and contact\nThis document provides necessary information for contributors to the workshop. For any further questions please do not hesitate to reach out to one of the local organizing committee members."
  },
  {
    "objectID": "software.html",
    "href": "software.html",
    "title": "Frequently asked questions for speakers, session chairs, and panelists",
    "section": "",
    "text": "Scope and contact\nThis document provides necessary information for contributors to the workshop. For any further questions please do not hesitate to reach out to one of the local organizing committee members."
  },
  {
    "objectID": "publications_stat.html",
    "href": "publications_stat.html",
    "title": "Statistical methodological publications",
    "section": "",
    "text": "math\n\n\n\n\n\n\n\n\nx\n\n\n\n\nErdmann (NA). Oncology clinical trial design planning based on a multistate model that jointly models progression-free and overall survival endpoints. NA, NA(NA), NA\n\n\nPolito (NA). Applying the Estimand and Target Trial frameworks to external control analyses using observational data: a case study in the solid tumor setting. NA, NA(NA), NA\n\n\nRufibach, K., Grinsted, L., Li, J., Weber, H.-J., Zheng, C. Zhou, J. (2023). Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions. Pharmaceutical Statistics, 22(22), 671-691\n\n\nRufibach, K., Stegherr, R., Schmoor, C., Jehl, V., Allignol, A., Boeckenhoff, A., Dunger-Baldauf, C., Eisele, L., K\"unzel, T., Kupas, K., Leverkus, F., Trampisch, M., Zhao, Y., Friede, Beyersmann, J. (2023). Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) – comparison of adverse event risks in randomized controlled trials. Statistics in Biopharmaceutical Research, NA(NA), NA\n\n\nRajeshwari, S., Barksdale, E., Marchenko, O., Jiang, Q., Ando, Y., Bloomquist, E., Coory, M., Crouse, M., Degtyarev, E., Framke, T., Freidlin, B., Gerber, D.E., Gwise, T., Josephson, F., Hess, L., Kluetz, P., Li, D., Mandrekar, S., Posch, M., Rantell, K., Ratitch, B., Raven, A., Roes, K., Rufibach, K., Sarac, S.B., Simon, R., Singh, H., Theoret, M., Thomson, A., Zuber, E., Shen, Y.L., Pazdur, R. (2023). Cancer Clinical Trials Beyond Pandemic: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. Statistics in Biopharmaceutical Research, 15(15), 444-449\n\n\nIonan (NA). Clinical and Statistical Perspectives on the Estimand Framework Implementation. NA, NA(NA), NA\n\n\nCollignon (NA). Estimands and Complex Innovative Designs. NA, NA(NA), NA\n\n\nKunzmann (NA). Conditional Power and Friends: The Why and How of (Un)planned, Unblinded Sample Size Recalculations in Confirmatory Trials. NA, NA(NA), NA\n\n\nManitz (NA). Estimands for Overall Survival in Clinical Trials with Treatment Switching in Oncology. NA, NA(NA), NA\n\n\nStegherr (NA). Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Estimation of adverse event risks. NA, NA(NA), NA\n\n\nKunzmann (NA). A review of Bayesian perspectives on sample size derivation for confirmatory trials. NA, NA(NA), NA\n\n\nBornkamp (NA). Principal Stratum Strategy: Potential Role in Drug Development. NA, NA(NA), NA\n\n\nSun (NA). Estimands in Hematology Trials. NA, NA(NA), NA\n\n\nStegherr (NA). Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study. NA, NA(NA), NA\n\n\nDegtyarev (NA). Assessing the impact of COVID-19 on the objective and analysis of oncology clinical trials - application of the estimand framework. NA, NA(NA), NA\n\n\nRufibach (NA). Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure Proportion - with an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia. NA, NA(NA), NA\n\n\nBeyer (NA). A multistate model for early decision making in oncology. NA, NA(NA), NA\n\n\nMeller (NA). Joint modelling of progression-free and overall survival and computation of correlation measures. NA, NA(NA), NA\n\n\nRufibach (NA). Treatment Effect Quantification for Time-to-event Endpoints - Estimands, Analysis Strategies, and beyond. NA, NA(NA), NA\n\n\nRufibach (NA). Bayesian Predictive Power: Choice of Prior and some Recommendations for its Use as Probability of Success in Drug Development. NA, NA(NA), NA\n\n\nAsikanius (NA). Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint. NA, NA(NA), NA\n\n\nRufibach (NA). Comparison of different clinical development plans for confirmatory subpopulation selection. NA, NA(NA), NA\n\n\nRufibach (NA). Sequentially Updating the Likelihood of Success of a Phase 3 Pivotal Time-To-Event Trial based on Interim Analyses or External Information. NA, NA(NA), NA\n\n\nDümbgen (NA). Maximum-Likelihood Estimation of a Log-Concave Density based on Censored Data. NA, NA(NA), NA\n\n\nBalabdaoui (NA). Asymptotics of the discrete log-concave maximum likelihood estimator and related applications. NA, NA(NA), NA\n\n\nRufibach (NA). A smooth ROC curve estimator based on log-concave density estimates.. NA, NA(NA), NA\n\n\nRufibach (NA). Selection models with monotone weight functions in meta analysis.. NA, NA(NA), NA\n\n\nDümbgen (NA). logcondens: Computations Related to Univariate Log-Concave Density Estimation.. NA, NA(NA), NA\n\n\nHeld (NA). A score regression approach to assess calibration of probabilistic predictions.. NA, NA(NA), NA\n\n\nBalabdaoui (NA). Least Squares estimation of two ordered monotone regression curves.. NA, NA(NA), NA\n\n\nRufibach (NA). The block criterion for multiscale inference about a density with applications to other multiscale problems.. NA, NA(NA), NA\n\n\nRufibach (NA). An Active Set Algorithm to Estimate Parameters in Generalized Linear Models with Ordered Predictors.. NA, NA(NA), NA\n\n\nRufibach (NA). reporttools: R Functions to Generate LaTeX Tables of Descriptive Statistics.. NA, NA(NA), NA\n\n\nMüller (NA). Smooth tail index estimation.. NA, NA(NA), NA\n\n\nBalabdaoui (NA). Limit distribution theory for maximum likelihood estimation of a log-concave density.. NA, NA(NA), NA\n\n\nDümbgen (NA). Maximum likelihood estimation of a log-concave density and its distribution function: basic properties and uniform consistency.. NA, NA(NA), NA\n\n\nMüller (NA). On the max-domain of attraction of distributions with log-concave densities.. NA, NA(NA), NA\n\n\nBalabdaoui (NA). A second Marshall inequality in convex estimation.. NA, NA(NA), NA\n\n\nRufibach (NA). Computing Maximum Likelihood Estimators of a log-concave Density Function.. NA, NA(NA), NA\n\n\nRufibach (NA). Eintrittsraten und Austrittswahrscheinlichkeiten EVK 2000.. NA, NA(NA), NA\n\n\n\n\n\n\n\nmathDisc\n\n\n\n\n\n\n\n\nx\n\n\n\n\nRufibach (NA). Proposal of the vote of thanks in discussion of Cule M. / Samworth R. and Stewart M.: Maximum likelihood estimation of a multidimensional logconcave density. NA, NA(NA), NA\n\n\n\n\n\n\n\nmathLetter\n\n\n\n\n\n\n\n\nx\n\n\n\n\nHampson (NA). Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: A landscape assessment. NA, NA(NA), NA\n\n\nDukes (NA). On Identification of the Principal Stratum Effect in Patients Who Would Comply If Treated. NA, NA(NA), NA\n\n\n\n\n\n\n\nmathProc\n\n\n\n\n\n\n\n\nx\n\n\n\n\nRufibach (NA). Criteria for multiscale inference. NA, NA(NA), NA\n\n\nDümbgen (NA). Marshall’s lemma for convex density estimation. NA, NA(NA), NA\n\n\n\n\n\n\n\nmed\n\n\n\n\n\n\n\n\nx\n\n\n\n\nBachy (NA). Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. NA, NA(NA), NA\n\n\nWeber (NA). MRI of the sacroiliac joints in athletes: Recognition of non-specific bone marrow edema by semi-axial added to standard semi-coronal scans. NA, NA(NA), NA\n\n\nWeber (NA). Frequency and anatomical distribution of magnetic resonance imaging features in sacroiliac joints of young athletes. NA, NA(NA), NA\n\n\nMarcus (NA). Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. NA, NA(NA), NA\n\n\nChristiansen (NA). Limited Reliability of Radiographic Assessment of Sacroiliac Joints in Patients with Suspected Early Spondyloarthritis. NA, NA(NA), NA\n\n\nWeber (NA). Does evaluation of the ligamentous compartment enhance diagnostic utility of sacroiliac joint MRI in axial spondyloarthritis?. NA, NA(NA), NA\n\n\nWeber (NA). Diagnostic Utility of Candidate Definitions for Demonstrating Axial Spondyloarthritis on Magnetic Resonance Imaging of the Spine. NA, NA(NA), NA\n\n\nSteiner (NA). An unexpected finding: younger fathers have a higher risk for offspring with chromosomal aneuploidies. NA, NA(NA), NA\n\n\nWeber (NA). Candidate lesion-based criteria for defining a positive sacroiliac joint MRI in two cohorts of patients with axial spondyloarthritis. NA, NA(NA), NA\n\n\nWeber (NA). Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis?. NA, NA(NA), NA\n\n\nBergsträsser (NA). The Paediatric Palliative Screening Scale: Further validity testing. NA, NA(NA), NA\n\n\nWeber (NA). Fat infiltration on MRI of the sacroiliac joints has limited diagnostic utility in non-radiographic axial spondyloarthritis. NA, NA(NA), NA\n\n\nCiurea (NA). Tumor necrosis factor-alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. NA, NA(NA), NA\n\n\nMueller-Pfeiffer (NA). Screening for Dissociative Disorders in Psychiatric Out- and Day Care-Patients. NA, NA(NA), NA\n\n\nMica (NA). The risk of early mortality of polytrauma patients associated to ISS / NISS / APACHE II values and prothrombin time. NA, NA(NA), NA\n\n\nSürder (NA). Intracoronary injection of bone marrow derived mononuclear cells early or late after acute myocardial infarction: Effects on global left ventricular function. NA, NA(NA), NA\n\n\nJurik (NA). Pitfalls in MR morphology of the sterno-costo-clavicular region by whole body MRI. NA, NA(NA), NA\n\n\nFaeh (NA). Population specific and up to date cardiovascular risk charts can be efficiently obtained with record linkage of routine and observational data. NA, NA(NA), NA\n\n\nSürder (NA). Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry. NA, NA(NA), NA\n\n\nKohl (NA). Does increased tumor burden of sentinel nodes in breast cancer affect detection procedure?. NA, NA(NA), NA\n\n\nWinklhofer (NA). MR imaging frequently changes classification of acute traumatic thoracolumbar spine injuries. NA, NA(NA), NA\n\n\nWeber (NA). Development and validation of an MRI reference criterion for defining a positive SIJ MRI in spondyloarthritis. NA, NA(NA), NA\n\n\nWulf (NA). Silver enhanced in-situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer. NA, NA(NA), NA\n\n\nInauen (NA). Quality of Life after Osteosynthesis of Fractures of the Proximal Humerus. NA, NA(NA), NA\n\n\nDjahangiri (NA). Outcome of single-tendon rotator cuff repair in patients aged older than 65 years. NA, NA(NA), NA\n\n\nGraf (NA). Frequency and Risk Factors of Lower Limb Lymphedema Following Lymphadenectomy in Patients with Gynecological Malignancies. NA, NA(NA), NA\n\n\nFroehlich (NA). Statin Therapy Reduces Cancer Risk and Mortality after Cardiac Transplantation. NA, NA(NA), NA\n\n\nWerner (NA). Normal values of Wiberg’s lateral center-edge angle and Lequesne’s acetabular index - a coxometric update. NA, NA(NA), NA\n\n\nWeber (NA). Can erosions on MRI of the sacroiliac joints be reliably detected in patients with ankylosing spondylitis? - A cross-sectional study. NA, NA(NA), NA\n\n\nMueller-Pfeiffer (NA). Global functioning and disability in dissociative disorders.. NA, NA(NA), NA\n\n\nEmler (NA). Pressure indices in peripheral arterial disease assessed by infrared photosensors.. NA, NA(NA), NA\n\n\nSpross (NA). The PHILOS Plate for Proximal Humeral Fractures - Risk Factors for Complications at one Year.. NA, NA(NA), NA\n\n\nPoletti-Muringaseril (NA). Low meningitis-incidence in primary spontaneous compared to secondary cerebrospinal fluid rhinorrhoea.. NA, NA(NA), NA\n\n\nHahn (NA). Physiological bone responses in the fingers after &gt;10 years of high level sport climbing.. NA, NA(NA), NA\n\n\nLawrence (NA). What is an estimand and how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials. NA, NA(NA), NA\n\n\nWeber (NA). Anterior chest wall inflammation by whole body MRI in patients with spondyloarthritis: Lack of association between clinical and imaging findings in a cross-sectional study.. NA, NA(NA), NA\n\n\nGuggenberger (NA). Diffusion tensor imaging of the median nerve: Intra- inter-reader agreement and agreement between two software packages.. NA, NA(NA), NA\n\n\nSoyka (NA). On the effectiveness of treatment options in epistaxis: An analysis on 678 patients.. NA, NA(NA), NA\n\n\nvon Websky (NA). Modifying the concept of Job Satisfaction for Surgical Training Programs: Modern management tools ensure trainee motivation and success.. NA, NA(NA), NA\n\n\nAllenspach (NA). Radiological changes and signs of osteoarthritis in the fingers of male performance sportclimbers.. NA, NA(NA), NA\n\n\nJaberg (NA). The prognostic value of N-terminal proBNP in patients with acute coronary syndromes undergoing left main PCI.. NA, NA(NA), NA\n\n\nBritschgi (NA). Modeling of pathological traits in Alzheimer’s disease based on extracellular signaling proteome.. NA, NA(NA), NA\n\n\nTaegtmeyer (NA). Electronic prescribing increases uptake of clinical pharmacologists’ recommendations in the hospital setting.. NA, NA(NA), NA\n\n\nSteurer-Dober (NA). Do Patients with MR Abnormalities of the Shoulder Experience Pain after MR Arthrography of the Shoulder?. NA, NA(NA), NA\n\n\nThalhammer (NA). Predictive value of duplex ultrasound for restenosis after renal artery stenting.. NA, NA(NA), NA\n\n\nSürder (NA). Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI).. NA, NA(NA), NA\n\n\nSoyka (NA). Is Severe Epistaxis Associated With Acetylsalicylic Acid Intake?. NA, NA(NA), NA\n\n\nNocito (NA). Placement of implantable venous access ports in oncologic surgery: A prospective randomized trial comparing venous cut-down versus Seldinger technique.. NA, NA(NA), NA\n\n\nBritschgi (NA). Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease.. NA, NA(NA), NA\n\n\nWeber (NA). Sensitivity and specificity of spinal inflammatory lesions assessed by whole body MRI in spondyloarthritis and recent-onset inflammatory back pain.. NA, NA(NA), NA\n\n\nWeber (NA). Assessment of acute spinal inflammatory changes in patients with spondyloarthritis: Validation of whole body MRI against conventional MRI.. NA, NA(NA), NA\n\n\nWeber (NA). Validation of whole body MRI against conventional MRI for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondyloarthritis.. NA, NA(NA), NA\n\n\nHermanns (NA). Is there a role for tamsulosin in the treatment of distal ureteral stones smaller than 7mm? Results of a randomised double-blind placebo-controlled trial.. NA, NA(NA), NA\n\n\nFurrer (NA). The value of ultrasonography in handsurgery.. NA, NA(NA), NA\n\n\nRuhstaller (NA). Breast Cancer Patients on Endocrine Therapy Reveal More Symptoms when Self-Reporting than in Pivotal Trials: An Outcome Research Study.. NA, NA(NA), NA\n\n\nMünger-Beyeler (NA). Quality of analgesic treatment in patients with advanced prostate cancer: Do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) Experience.. NA, NA(NA), NA\n\n\nRoth (NA). Docetaxel-Cisplatin-5FU versus Docetaxel-Cisplatin versus Epirubicin-Cisplatin-5FU as systemic treatment for advanced gastric carcinoma: A randomized phase II trial of the SAKK.. NA, NA(NA), NA\n\n\nRibi (NA). Endocrine symptom assessment in women with breast cancer: what a simple ``yes’’ means.. NA, NA(NA), NA\n\n\nGhielmini (NA). Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors which are predictive of response and event free survival as well as the effect of rituximab on the immune system.. NA, NA(NA), NA\n\n\nTaussky (NA). Risk factors for developing a second aerodigestive cancer after radiotherapy with or without chemotherapy for head and neck cancer: An exploratory outcome analysis.. NA, NA(NA), NA\n\n\nHuguenin (NA). Concomitant Cisplatin Significantly Improves Loco-Regional Control in Advanced Head and Neck Cancers Treated with Hyperfractionated Radiotherapy.. NA, NA(NA), NA\n\n\n\n\n\n\n\nmedContr\n\n\n\n\n\n\n\n\nx\n\n\n\n\nRufibach (NA). Assessment of paired binary data. NA, NA(NA), NA\n\n\n\n\n\n\n\nmedLetter\n\n\n\n\n\n\n\n\nx\n\n\n\n\nRufibach (NA). Use of Brier Score to assess binary predictions. NA, NA(NA), NA\n\n\nZenhäusern (NA). Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia - a multicentre trial SAKK 32/95. NA, NA(NA), NA\n\n\nHerrmann (NA). Perioperative and adjuvant chemotherapy in colon cancer: results of SAKK trial 40/93. NA, NA(NA), NA\n\n\n\n\n\n\n\nSubmitted\n\n\nPublished"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "About",
    "section": "",
    "text": "About\n\n\n\n\n\n\n\n\n\nMethods, Collaboration, and Outreach Group (MCO), Product Development Data Sciences, F. Hoffmann-La Roche, Basel, Switzerland   Linkedin  Google scholar  Pubmed  arxiv\n\n\n\n\n\nI am a mathematical statistician. Through more than 20 years in various biostatistical roles I have complemented my thorough theoretical background with expertise in biostatistics. I am passionate about applying this expertise to solve problems in pharmaceutical drug development.\nI am an Accredited European Statistician, a qualification issued by The Federation of European National Statistical Societies.\n CV  Publications  Talks  Teaching\n\n\nInterests\n\nStatistical methods to optimize clinical trial designs\nAdvanced survival analysis\nProbability of success\nEstimands and causal inference\nNonparametric statistics\n\n\n\nEducation\n\nPostdoc in Mathematical Statistics, 2007, Stanford University, United States\nPhD in Mathematics, 2006, University of Bern, Switzerland\nMSc in Mathematical Statistics and Actuarial Science, 2001, University of Bern, Switzerland"
  },
  {
    "objectID": "textbook.html",
    "href": "textbook.html",
    "title": "Frequently asked questions for speakers, session chairs, and panelists",
    "section": "",
    "text": "Scope and contact\nThis document provides necessary information for contributors to the workshop. For any further questions please do not hesitate to reach out to one of the local organizing committee members."
  },
  {
    "objectID": "talks.html",
    "href": "talks.html",
    "title": "Frequently asked questions for speakers, session chairs, and panelists",
    "section": "",
    "text": "Scope and contact\nThis document provides necessary information for contributors to the workshop. For any further questions please do not hesitate to reach out to one of the local organizing committee members."
  },
  {
    "objectID": "working.html",
    "href": "working.html",
    "title": "Frequently asked questions for speakers, session chairs, and panelists",
    "section": "",
    "text": "Scope and contact\nThis document provides necessary information for contributors to the workshop. For any further questions please do not hesitate to reach out to one of the local organizing committee members."
  }
]